Global Industry Analysts, Inc., Oct 2011, Pages: 897
.Market Analysis 197
Current and Future Analysis 197
Regional Perspective 197
Advancements in BreastCancer Treatment in Europe 198
New Formulations that are Under Clinical Trials 198
Drugs Undergoing Trials
Global Industry Analysts, Inc., Oct 2011, Pages: 323
of strategic acquisitions and alliances, strengthening R&D activities, and exploring newer markets to reinforce their network for more effective diagnosis as well as treatment of breastcancer.
Despite
Global Industry Analysts, Inc., Oct 2006, Pages: 563
Perspective for BreastCancer
Therapeutics by Product Segment- Hormonal Therapy and
Chemotherapy Markets for 2000, 2006, and 2010 III-53
2f. Rest of Europe III-54
A.Market Analysis III-54
Highlights III
Global Industry Analysts, Inc., Feb 2011, Pages: 682
. EUROPE 148
A.Market Analysis 148
Facet of Angiogenesis in the European Market 148
Angiogenesis Market - A Historic Perspective 148
Cancer Trends 148
Table 26: Cancer Incidence in Europe by Site (2009
Timely Data Resources, Inc., Feb 2012
?
A: The IPD will be of particular interest to those involved in market research, product development, strategic planning, new business development, clinical research, licensing, stock market analysis
Global Industry Analysts, Inc., Oct 2010, Pages: 360
Cost of Radiation Therapy 55
Limitations of Conventional Radiation Therapy Techniques 56
9. CANCER TREATMENT - A COSTANALYSIS
GBI Research, May 2011, Pages: 93
. The A provides an in-depth analysis of the trials conducted by major pharmaceutical companies for the top five oncology therapeutic indications, which are breastcancer, colorectal cancer, prostate cancer, lung
Global Industry Analysts, Inc., July 2009, Pages: 558
-6
Tough Regulatory Riders Threaten to Slow Down Number of
Approvals II-6
Spiraling Cost of Next Generation Cancer Drugs
Global Industry Analysts, Inc., Oct 2006, Pages: 387
, BreastCancer, and Malignant Melanoma (includes
corresponding Graph/Chart) II-8
An Insight into Colorectal Cancer Therapeutic Alternatives II-9
2. Market Pulse II-10
Is Huge Cost of Drugs a Major
Global Industry Analysts, Inc., Aug 2011, Pages: 1305
to growing number of cancer biomarkers receiving regulatory clearances. Cardiology is expected to emerge as the fastest growing segment in terms of therapeutics with a CAGR of about 24% over the analysis
Global Industry Analysts, Inc., Oct 2008, Pages: 232
Dimensions for Paclitaxel II-13
Clinical Research Favors Paclitaxel for BreastCancer Treatment II-13
American BioScience’ Nab Technology Unveils Higher Tissue
Decision Resources, Inc., June 2009, Pages: 30
companion diagnostics; the looming question in this field is: How many will follow, and will this become a major strategy?
- Breastcancer has emerged as a hotbed of development for personalized medicine
TriMark Publications, July 2011, Pages: 201
to Predictive Medicine
6.28 Analysis of Cost-Effectiveness at the Individual Level
6.29 The Patient and Advocate Perspective: An Evolution of Influence
6.30 Real-World Experiences Translating the Vision
Global Industry Analysts, Inc., Sep 2011, Pages: 428
, and prescribing physicians as well. The reason being systemic absorption of HRT drugs resulting in increased risk of breastcancer, stroke and cardiovascular diseases that outweighed the benefit of lowered risk
Global Industry Analysts, Inc., Aug 2011, Pages: 239
. GLOBAL MARKET PERSPECTIVE 56
Table 1: World Recent Past Current & Future Analysis for
Molecular Cytogenetics Technologies by Geographic Region -
North America, Europe, and Rest of World Independently
Global Industry Analysts, Inc., Oct 2011, Pages: 261
Techniques 12
Digital Cameras Debut the Market 12
Breast-Specific Gamma Cameras Detect Small Cancer Lesions 12
Growing Collaboration Between Gamma Camera Makers &
Pharmaceutical Companies 13
6
Markets and Markets, Sep 2009, Pages: 256
analysis
2. SUMMARY
3. BIOMARKER MARKET DYNAMICS
3.1. Drivers
3.1.1. high demand for biomarkers in drug discovery
3.1.2. Biomarkers help in the Early detection of drug failures
3.1.3. Biomarkers as cancer
